This post was last updated on September 8th, 2019 at 12:06 pm
Opioid epidemic crisis in the United States and the need for substantial measures to avoid spreading the use of harmful substances, has finally gained some ground in the nation. On Tuesday, a US district judge ruled that cases against drug companies over drug epidemic can go to trial. The announcement came even as Prude Pharma avowed offering a compensation to those impacted.
US District Judge Dan Polster, currently looking into about 2,000 opioid cases by state and local governments against drug makers and pharmaceutical firms, ruled that governments can move ahead and try to prove drug makers’ marketing of prescription of opioid painkillers, caused an oversupply, which pharmacies and other drug agents did not stop.
“A factfinder could reasonably infer that these failures were a substantial factor in producing the alleged harm suffered by plaintiffs,” the judge wrote in his statement.
The ruling was among seven decisions totaling 80 pages released by Polster. Purdue Pharma, maker of OxyContin accused of spreading the epidemic, accumulates for twenty-one trials by two Ohio counties. Polster in his pages also refused to abandon conspiracy claims against drug makers and its distributors.
Apart from it, other defendants included drug makers Endo International Plc and Johnson & Johnson; pharmacy operators CVS Health Corp, Rite Aid Corp, Walgreens Boots Alliance Inc. and Walmart Inc; and distributors AmerisourceBergen Corp, Cardinal Health Inc. and McKesson Corp. Consequently, Polster also refused several other dismal requests against drug makers and pharmacies.
Paul Hanly, a lawyer for the plaintiffs said, his clients were delighted that Polster “almost uniformly” nudged positively on their positions of the dismissal pleas and whether to admit various testimonies.
As per Centers for Disease Control and Prevention, Opioid epidemic crisis in the United States in the last two decades has seen more than 400,000 deaths. A major cause of which is the easy availability of drugs, and the prescription pattern followed in the nation.